Search clinical trials for: Adenosine 2A Receptor Antagonist

Total 42762 results

University of Florida
ALS Association

Recruiting

Adenosine 2A Receptor Antagonism and AIH in ALS

ALS

United States
AstraZeneca

Completed

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Biogen

Withdrawn

BIIB014 Phase 2a Monotherapy

Parkinson's Disease
AstraZeneca
Parexel

Completed

A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers

Healthy Volunteer/DDI Study

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

Chronic Hepatic Impairment
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Metastatic Breast Cancer

United States
Rigshospitalet, Denmark

Recruiting

LSD Occupancy of the Serotonin 2A Receptor in the Human Brain (dOccLS)

Basic Science

Denmark
Ohio State University
ACADIA Pharmaceuticals Inc.

Not yet recruiting

Pimavanserin and Aggression and Social Cognition.

Intermittent Explosive Disorder

United States
M.D. Anderson Cancer Center

Recruiting

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Renal Cell Carcinoma

United States
Vanderbilt University Medical Center
ACADIA Pharmaceuticals Inc.

Recruiting

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Parkinson Disease | Neurodegenerative Diseases | Parkinson Disease Psychosis

United States
Virginia Commonwealth University
Kyowa Kirin, Inc.

Recruiting

Istradefylline for Parkinson Disease With Cognitive Impairment

Parkinson Disease | Cognitive Impairment

United States
Dwight Owen
National Cancer Institute (NCI)

Recruiting

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Randy Trumbower, PT, PhD

Not yet recruiting

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

Spinal Cord Injuries | Myelopathy

United States
University of Messina
Natasha Irrera; Gianluca Di Bella; Antonio Micari; Roberto Licordari

Recruiting

Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction (BETA-MI)

Myocardial Infarction | Myocardial Fibrosis | Myocardial Remodeling, Ventricular

Italy
Weill Medical College of Cornell University
Arcus Biosciences, Inc.

Recruiting

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. (PANTHER)

Rectal Cancer

United States
University Hospital, Strasbourg, France
EUCLID Clinical Trial Platform; NS-PARK; F-CRIN

Recruiting

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (PIMPARK)

Parkinson Disease

France
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)

Prostatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic Neoplasms

United States, Canada
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Terminated

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Parkinson's Disease

United States
Coherus Biosciences, Inc.
Arcus Biosciences, Inc.; Surface Oncology

Terminated

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Canada
Kyowa Kirin, Inc.

Completed

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Parkinson's Disease

United States
Kyowa Kirin, Inc.

Completed

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

Parkinson's Disease

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease (KW-6002)

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Kirin, Inc.
Kyowa Hakko Kirin UK, Ltd.

Completed

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Parkinson's Disease

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

Sleep Disorder | Restless Legs Syndrome

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

Parkinson's Disease

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

Hepatic Impairment

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study to Evaluate Abuse Potential of Istradefylline

Drug Abuse

United States
Kyowa Kirin, Inc.

Completed

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Parkinson's Disease

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

Parkinson's Disease | Movement Disorder Syndrome

United States
Kyowa Kirin, Inc.

Completed

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

Parkinson's Disease

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin UK, Ltd.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Parkinson's Disease

United Kingdom
Kyowa Kirin, Inc.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Parkinson's Disease

United States
RTI International
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Enrolling by invitation

Early Check: Expanded Screening in Newborns

Primary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditions

United States
Medical University of South Carolina
Kyowa Kirin, Inc.

Terminated

Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.

Parkinson Disease | Apathy

United States
Jennifer Choe
Arcus Biosciences, Inc.

Withdrawn

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Oropharynx Cancer | Oral Cavity Cancer | Oropharynx Squamous Cell Carcinoma | Pharynx Cancer | Larynx Cancer | Hypopharynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma

United States
Georgetown University
Kyowa Kirin, Inc.

Active, not recruiting

Istradefylline Effect Protocol on Parkinson's Disease Tremor

Parkinson Disease | Tremor

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First in Human Study of M1069 in Advanced Solid Tumors

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada
Biogen

Completed

Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency (TRIDENT-1)

Renal Insufficiency | Congestive Heart Failure

Israel, Italy, United States, Finland, Canada, Australia, France, Netherlands, Poland, Bulgaria, Russian Federation, India, Brazil, Sweden, Romania, Czechia, Argentina, Germany
Biogen

Terminated

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency (POSEIDON)

Heart Failure | Renal Insufficiency

United States
Biogen

Completed

BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

Healthy

United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Hematopoietic and Lymphoid Cell Neoplasm | Sarcoma | Lymphoma | Breast Carcinoma

United States
Hoffmann-La Roche

Terminated

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)

Breast Cancer

Italy, United States, Korea, Republic of, Canada, Czechia, Spain, Australia, Bulgaria, China, Finland, France, Greece, Poland, Portugal, Taiwan, Thailand, Turkey, Colombia, Bosnia and Herzegovina, Mexico, Peru, Romania, Russian Federation and more
University of Sao Paulo

Completed

Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel

Coronary Artery Disease

Brazil
Palobiofarma SL
Novartis; H. Lee Moffitt Cancer Center and Research Institute

Completed

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO)

Non-small Cell Lung Cancer (NSCLC)

United States
Colorado State University

Withdrawn

Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training

Vasodilation | Vasoconstriction

United States
Bjorn H. Ebdrup
Rigshospitalet, Denmark; ACADIA Pharmaceuticals Inc.; GCP unit, Copenhagen University...

Withdrawn

The Sub-Sero Study

Schizophrenia | Psychosis
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
Centro Prevenzione Malattie Cardiovascolari N....
Gruppo Italiano Multidisciplinare per lo Studio della Sincope

Completed

Theophylline for Low Adenosine Syncope (THEO-USA)

Syncope

Italy
Versiti
Dana-Farber Cancer Institute; University of Illinois at Chicago; Medical College... and other collaborators

Unknown

Microvascular Blood Flow in Sickle Cell Anemia

Sickle Cell Disease | Sickle Cell Anemia

United States

Search clinical trials for: Adenosine 2A Receptor Antagonist

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations